Chimerix, Inc., a developing-stage biopharmaceutical company, focuses on accelerating the advancement of various drugs that impact the lives of patients living with cancer and other serious diseases. The company is headquartered in Durham, North Carolina.
| Revenue (TTM) | 212,000 |
| Gross Profit (TTM) | $-74.36M |
| EBITDA | $-96.47M |
| Operating Margin | -43074.00% |
| Return on Equity | -56.20% |
| Return on Assets | -33.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.32 |
| Price-to-Book | 6.58 |
| Price-to-Sales (TTM) | 3778.70 |
| EV/Revenue | 3159.9 |
| EV/EBITDA | 1.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1325.00% |
| Shares Outstanding | $93.80M |
| Float | $80.44M |
| % Insiders | 1.73% |
| % Institutions | 56.44% |
Volatility is currently contracting